These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11363390)

  • 1. Getting your space on the magic crixi-van.
    Gilden D
    GMHC Treat Issues; 1996 Mar; 10(3):4. PubMed ID: 11363390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indinavir (Crixivan), Merck protease inhibitor, approved.
    James JS
    AIDS Treat News; 1996 Mar; (no 243):1-2. PubMed ID: 11363299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indinavir (Crixivan) access and distribution.
    James JS
    AIDS Treat News; 1996 Apr; (no 244):3-5. PubMed ID: 11363304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment briefs.
    Gilden D
    GMHC Treat Issues; 1995 Apr; 9(4):6. PubMed ID: 11362367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More pharmacies to carry Crixivan.
    GMHC Treat Issues; 1997 Mar; 11(3):8-9. PubMed ID: 11364278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indinavir: lightening the load.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1996 Aug; 2(8):6-11. PubMed ID: 11363759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merck protease inhibitor available to persons with CD4 count 50 or less--must register by August 11.
    AIDS Treat News; 1995 Jul; (no 227):1-2. PubMed ID: 11362618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA approves 2 new protease inhibitors: ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration.
    Schouten JT
    STEP Perspect; 1996; 8(1):7-8. PubMed ID: 11363592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indinavir approved for HIV infection.
    Am Fam Physician; 1996 May; 53(6):2203. PubMed ID: 8623727
    [No Abstract]   [Full Text] [Related]  

  • 10. Indinavir (Crixivan).
    Treat Rev; 1996 Apr; (no 21):7. PubMed ID: 11363398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Merck's protease inhibitor expanded access program now open.
    Smart T; Torres G
    GMHC Treat Issues; 1995; 9(7/8):10. PubMed ID: 11362649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA approves nelfinavir. Food and Drug Administration.
    GMHC Treat Issues; 1997 Mar; 11(3):8. PubMed ID: 11364277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Merck expanded access program August 11, 1995 deadline.
    Treat Rev; 1995; (no 19):3. PubMed ID: 11362754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glaxo, Merck and ADAP.
    GMHC Treat Issues; 1996 May; 10(5):8. PubMed ID: 11363584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease inhibitor studies enrolling.
    Treat Rev; 1995; (no 17):3. PubMed ID: 11362296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fourth protease inhibitor hits the market.
    AIDS Alert; 1997 May; 12(5):59-60. PubMed ID: 11364224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Freedom of choice.
    Vazquez E
    Posit Aware; 1996; 7(3):9, 19. PubMed ID: 11363432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease inhibitors.
    Treat Rev; 1996 Aug; (No 22):2-7. PubMed ID: 11363815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease inhibitor: Roche lottery deadline July 21.
    AIDS Treat News; 1995 Jul; (no 226):4-5. PubMed ID: 11362614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roche and Merck begin expanded access programs for protease inhibitor drugs.
    Baker R
    BETA; 1995 Sep; ():4. PubMed ID: 11362890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.